These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22591029)

  • 1. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft.
    Alachkar N; Bagnasco SM; Montgomery RA
    Transpl Int; 2012 Aug; 25(8):e93-5. PubMed ID: 22591029
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.
    Larrea CF; Cofan F; Oppenheimer F; Campistol JM; Escolar G; Lozano M
    Transplantation; 2010 Apr; 89(7):903-4. PubMed ID: 20386298
    [No Abstract]   [Full Text] [Related]  

  • 3. Posttransplant recurrence of atypical hemolytic uremic syndrome.
    Valoti E; Alberti M; Noris M
    J Nephrol; 2012; 25(6):911-7. PubMed ID: 22760880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.
    Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T
    Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome.
    Cañigral C; Moscardó F; Castro C; Pajares A; Lancharro A; Solves P; de la Rubia J; Carpio N; Sanz MA
    Ann Hematol; 2014 Aug; 93(8):1421-2. PubMed ID: 24306089
    [No Abstract]   [Full Text] [Related]  

  • 7. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Noris M; Remuzzi G
    Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):704-12. PubMed ID: 24076560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical grand rounds: atypical hemolytic uremic syndrome.
    Hodgkins KS; Bobrowski AE; Lane JC; Langman CB
    Am J Nephrol; 2012; 35(5):394-400. PubMed ID: 22517061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab for atypical hemolytic-uremic syndrome.
    Nürnberger J; Philipp T; Witzke O; Opazo Saez A; Vester U; Baba HA; Kribben A; Zimmerhackl LB; Janecke AR; Nagel M; Kirschfink M
    N Engl J Med; 2009 Jan; 360(5):542-4. PubMed ID: 19179328
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.
    Reuter S; Heitplatz B; Pavenstädt H; Suwelack B
    Transplantation; 2013 Nov; 96(10):e74-6. PubMed ID: 24247905
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemolytic uremic syndrome following Campath-1H induction.
    Bonatti H; Brandacher G; Boesmueller C; Cont M; Hengster P; Rosenkranz AR; Krugmann J; Margreiter R
    Transpl Int; 2007 Apr; 20(4):386-9. PubMed ID: 17326780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.
    Châtelet V; Lobbedez T; Frémeaux-Bacchi V; Ficheux M; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2010 Dec; 42(10):4353-5. PubMed ID: 21168697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome.
    Prescott HC; Wu HM; Cataland SR; Baiocchi RA
    Am J Hematol; 2010 Dec; 85(12):976-7. PubMed ID: 20941783
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab.
    Zschiedrich S; Prager EP; Kuehn EW
    Ann Intern Med; 2013 Jul; 159(1):76. PubMed ID: 23817717
    [No Abstract]   [Full Text] [Related]  

  • 15. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
    Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
    Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
    Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
    N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab.
    Wilson CH; Brown AL; White SA; Goodship TH; Sheerin NS; Manas DM
    Transplantation; 2011 Oct; 92(8):e42-3. PubMed ID: 21989273
    [No Abstract]   [Full Text] [Related]  

  • 18. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of atypical hemolytic uremic syndrome successfully weaned from plasma exchange by treatment with eculizumab].
    Nagata A; Ohara A; Wakasugi D; Natori C; Ito S; Taguchi K; Fukami K; Okuda S
    Nihon Jinzo Gakkai Shi; 2014; 56(5):606-11. PubMed ID: 25130033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living-donor kidney transplantation for atypical haemolytic uremic syndrome with pre-emptive eculizumab use.
    Parikova A; Fronek JP; Viklicky O
    Transpl Int; 2015 Mar; 28(3):366-9. PubMed ID: 25256057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.